FibroGen, Inc (FGEN): Price and Financial Metrics


FibroGen, Inc (FGEN)

Today's Latest Price: $45.49 USD

0.27 (-0.59%)

Updated Oct 20 4:00pm

Add FGEN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

FGEN Stock Summary

  • The price/operating cash flow metric for Fibrogen Inc is higher than 98.39% of stocks in our set with a positive cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Fibrogen Inc is reporting a growth rate of -648.09%; that's higher than just 2.82% of US stocks.
  • As for revenue growth, note that FGEN's revenue has grown -69.24% over the past 12 months; that beats the revenue growth of just 2.35% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Fibrogen Inc, a group of peers worth examining would be AMPH, PXLW, MXL, CAPR, and GNTX.
  • FGEN's SEC filings can be seen here. And to visit Fibrogen Inc's official web site, go to www.fibrogen.com.

FGEN Stock Price Chart Interactive Chart >

Price chart for FGEN

FGEN Price/Volume Stats

Current price $45.49 52-week high $51.56
Prev. close $45.76 52-week low $22.65
Day low $45.21 Volume 421,684
Day high $46.97 Avg. volume 693,402
50-day MA $43.88 Dividend yield N/A
200-day MA $40.33 Market Cap 4.11B

FibroGen, Inc (FGEN) Company Bio


Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.

FGEN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$45.49$0.97 -98%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Fibrogen Inc. To summarize, we found that Fibrogen Inc ranked in the 4th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for FGEN, they are:

  • The company has produced more trailing twelve month cash flow than only 17.69% of its sector Healthcare.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 5.6% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Fibrogen Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -116.26. This coverage rate is greater than that of merely 1.81% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-98%
1%-98%
2%-98%
3%-98%
4%-98%
5%-98%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as FGEN, try ATRS, IVC, PHG, SSKN, and DRRX.


FGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream


Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about Fibrogen Inc that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

Thinking about trading options or stock in FibroGen Inc, Beyond Meat, Eli Lilly, Bank of America, or Tesla?

NEW YORK , Sept. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FGEN, BYND, LLY, BAC, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score report. Full story available on Benzinga.com

Benzinga | September 3, 2020

FibroGen's (FGEN) CEO Enrique Conterno on Q2 2020 Results - Earnings Call Transcript

FibroGen, Inc. (FGEN) Q2 2020 Earnings Conference Call August 06, 2020 5:00 PM ET Company Participants Michael Tung – Vice President-Corporate Strategy and Investor Relations Enrique Conterno – Chief Executive Officer Pat Cotroneo – Chief Financial Officer Chris Chung – Senior Vice President-China Operations Thane Wettig – Chief Commercial Officer...

SA Transcripts on Seeking Alpha | August 7, 2020

FibroGen Reports Second Quarter 2020 Financial Results

- Strong Second Quarter China Roxadustat Net Sales of $15.7 million -- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN…

GlobeNewswire | August 6, 2020

Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo 2.20%
3-mo 5.18%
6-mo 15.37%
1-year 15.93%
3-year -16.76%
5-year 109.73%
YTD 6.06%
2019 -7.32%
2018 -2.36%
2017 121.50%
2016 -29.77%
2015 11.45%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8086 seconds.